US-FDA-approves-finerenone-treatment-patients-chronic-kidney-disease-associated-2-diabetes

Finerenone is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes / Despite guideline-directed therapies, many patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) still progress to loss of kidney function and are at high risk for cardiovascular events / By blocking MR overactivation, a key driver of CKD progression, finerenone works on a pathway largely unaddressed by existing treatments for CKD in T2D
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news